Recent Updates
Recently added Catalysts

V118E

Phase 1

Healthy | Monoclonal antibody | Other |Merck & Company, Inc.|Last Updated: Feb 27, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindACTIVE_CONTROLLED
Total Trials1
Total Enrollment126
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT07168915A Study of V118E in Healthy Participants (V118E-003)PHASE1 RECRUITING 126Oct 8, 2025Nov 12, 2027Feb 27, 20264 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants With Solicited Injection-Site Adverse Events (AEs)
Up to approximately 7 days after each vaccination

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, which occurs during the course of the study. A solicited AE is a predefined event that participants are specifically asked about and record on their vaccine report card (VRC). Solicited injection-site AEs include redness, swelling, and pain or tenderness. The number of participants with a solicited injection-site AE will be reported.

Number of Participants With Solicited Systemic AEs
Up to approximately 7 days after each vaccination

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, which occurs during the course of the study. A solicited AE is a predefined event that participants are specifically asked about and record on their VRC. Solicited systemic AEs include fever, muscle aches all over body, joint pain, headache, and tiredness. The number of participants with a solicited systemic AE will be reported.

Number of Participants With Immediate AEs Following Vaccination
Up to approximately 30 minutes after each vaccination

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, which occurs during the course of the study. The number of participants with immediate AEs following vaccination will be reported.

Number of Participants With Unsolicited AEs
Up to approximately 28 days after each vaccination

An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, which occurs during the course of the study. An unsolicited AE is an event that is not solicited using a VRC and that is communicated by a participant. The number of participants who experience an unsolicited AE will be reported.

Number of Participants With a Serious Adverse Event (SAE)
Up to approximately 12 months after final vaccination

An SAE is defined as any untoward medical occurrence that at any dose, results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or is a congenital anomaly/birth defect. The number of participants who experience an SAE will be reported.

Number of Participants With a Medically Attended Adverse Event (MAAE)
Up to approximately 12 months after final vaccination

A MAAE is defined as an adverse event in which medical attention is received during an unscheduled, non-routine outpatient visit, such as an emergency department visit, office visit, or an urgent care visit with any medical personnel for any reason. The number of participants who experience a MAAE will be reported.

Number of Participants With an Adverse Events of Special Interest (AESI)
Up to approximately 12 months after final vaccination

AESIs are selected serious and nonserious AEs which include but are not limited to: 1) Potential drug-induced liver injury (DILI) events defined as an elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) laboratory value that is ≥3\* the upper limit of normal (ULN) and an elevated total bilirubin laboratory value that is ≥2\* the ULN and, at the same time, an alkaline phosphatase laboratory value that is \<2\* the ULN, as determined by way of protocol-specified laboratory testing or unscheduled laboratory testing. 2) an overdose of V118E. 3) Potential immune-mediated disease (pIMDs) defined as a subset of AEs that an established autoimmune disease(s) AND inflammatory and/or neurologic disorder(s), which might or might not have an autoimmune etiology. The number of participants who experience an AESI will be reported.

Secondary Endpoints
Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs)
Day 28 Postvaccination 1
Change From Baseline in Serotype-specific IgG GMCs
Baseline and Day 28 Postvaccination 1
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelSEQUENTIAL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
V118EEXPERIMENTALParticipants receive intramuscular (IM) injection of V118E in a 2-dose regimen administered on Day 1 and Day 29.
PREVNAR 20™ + SalineACTIVE_COMPARATORParticipants receive one dose of IM injection of PREVNAR 20™ in a 2-dose regimen on Day 1 followed by one dose of saline on Day 29.
Interventions
NameTypeDescription
V118EBIOLOGICALIM administration
PREVNAR 20™BIOLOGICALIM administration
SalineBIOLOGICALIM administration
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 49 Years
SexALL
Healthy VolunteersYes
Study Sites4

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: \- Is in good health before randomization Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has a history of invasive pneumococcal disease or known history...

Countries:United States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT07168915primaryCompletionDate: changed
LOWMay 24, 2026NCT07168915studyFirstPostDate: changed